- Home
- LEXX vs LGVN Comparison
LEXX vs LGVN Comparison
Compare LEXX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- LGVN
- Stock Information
- Founded
- LEXX 2004
- LGVN 2014
- Country
- LEXX Canada
- LGVN United States
- Employees
- LEXX N/A
- LGVN N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- LEXX Health Care
- LGVN Health Care
- Exchange
- LEXX Nasdaq
- LGVN Nasdaq
- Market Cap
- LEXX 20.9M
- LGVN 23.4M
- IPO Year
- LEXX N/A
- LGVN 2021
- Fundamental
- Price
- LEXX $0.98
- LGVN $1.24
- Analyst Decision
- LEXX Strong Buy
- LGVN Strong Buy
- Analyst Count
- LEXX 1
- LGVN 3
- Target Price
- LEXX $7.00
- LGVN $8.67
- AVG Volume (30 Days)
- LEXX 90.9K
- LGVN 123.3K
- Earning Date
- LEXX 07-11-2025
- LGVN 05-08-2025
- Dividend Yield
- LEXX N/A
- LGVN N/A
- EPS Growth
- LEXX N/A
- LGVN N/A
- EPS
- LEXX N/A
- LGVN N/A
- Revenue
- LEXX $525,923.00
- LGVN $2,225,000.00
- Revenue This Year
- LEXX $0.62
- LGVN N/A
- Revenue Next Year
- LEXX $14.19
- LGVN $17.49
- P/E Ratio
- LEXX N/A
- LGVN N/A
- Revenue Growth
- LEXX 29.95
- LGVN 127.50
- 52 Week Low
- LEXX $0.95
- LGVN $0.77
- 52 Week High
- LEXX $4.44
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- LEXX 38.55
- LGVN 40.75
- Support Level
- LEXX $1.00
- LGVN $1.24
- Resistance Level
- LEXX $1.05
- LGVN $1.37
- Average True Range (ATR)
- LEXX 0.05
- LGVN 0.08
- MACD
- LEXX 0.01
- LGVN -0.01
- Stochastic Oscillator
- LEXX 28.80
- LGVN 15.79
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.